Conditions: Breast Cancer Hypercalcemia of Malignancy Colon Cancer Endocrine Cancer Head and Neck Cancer Kidney Cancer Lung Cancer Lymphoma Metastatic Cancer Multiple Myeloma Parathyroid Neoplasms Renal Cancer Thyroid Cancer Hodgkin's Lymphoma Non-Hodgkin's Lymphoma Non-Small Cell Lung Cancer
Keywords: hypercalcemia calcium bisphosphonates denosumab amgen malignancy 20070315 HMC oncology hematology
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 33
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium \</= 11.5 mg/dL (2.9 millimoles /L) by day 10.

Detailed description:

Arms:
arm 1: Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.

Interventions: intervention 1: denosumab
Intervention descriptions: intervention 1: 120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.

Protocol document: